Caitong International Asset Management’s BridgeBio Oncology BBOT Stock Holding History

Caitong International Asset Management’s Portfolio BBOT Stock Details BBOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$282	Buy	37 +33	+825%	+$275	﹤0.01%	1912
2026 Q1	$36	Buy	+4	New	+$43	﹤0.01%	2038

Other funds holding BBOT

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Caitong International Asset Management's BBOT Position: Q2 2026 in Review

Caitong International Asset Management increased its BridgeBio Oncology (BBOT) stake by 825% in Q2 2026, buying an estimated $275 and bringing the position to 37 shares worth $282. The position accounts for ﹤0.01% of the portfolio, ranked #1912.

Caitong International Asset Management first reported a position in BBOT in Q1 2026 and has held it in 2 quarters since. 4 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

Caitong International Asset Management held 37 shares of BridgeBio Oncology worth $282 as of Q2 2026.
Caitong International Asset Management bought 33 BridgeBio Oncology shares in Q2 2026, an estimated $275.
BridgeBio Oncology made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #1912 holding.
Caitong International Asset Management first reported a position in BridgeBio Oncology in Q1 2026 and has held it in 2 quarters since.
4 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.